Spotify stock plummets after earnings beat expectations as guidance disappoints
The Swedish audiostreamer’s soft guidance overshadowed an earnings beat.
United Arab Emirates to leave OPEC May 1, energy chief says still committed to oil price stability
The UAE said it decided leaving OPEC was in its national interest after reviewing its production policy and capacity.
OpenAI reportedly missed revenue targets. Shares of Oracle and these chip stocks are falling
OpenAI has recently missed its own projections for user growth and revenue, the WSJ reported.
This is not a stock picker’s market, says head of Norway’s $2 trillion wealth fund
Although he touted the fund’s strategy against an uncertain backdrop, Nicolai Tangen conceded that “If markets go down, we’ll go down too.”
Starbucks’ turnaround enters a new phase: Investors want stronger profits served
CEO Brian Niccol has sales going in the right direction. Now, investors want to see profits follow suit.
Citi UK CEO: ‘Phenomenal’ market resilience is keeping recession risk at bay — for now
Markets have performed in an orderly way, despite the economic turmoil wrought by Middle East war, said Citi UK CEO Tiina Lee.
U.S. is ‘being humiliated by Iran,’ says Germany’s Merz, as Europe’s patience wanes
The U.S. is being “humiliated” by the Iranian regime, Germany’s chancellor has said, as European leaders grow increasingly frustrated at the war with Iran.
‘Draconian development’ in Meta-Manus deal draws the line in China’s AI race with the U.S.
Beijing’s decision to block Meta’s acquisition of Manus is a warning to other startups thinking of relocating data, talent and intellectual property abroad.
U.S. is being ‘humiliated’ by Iran, says German Chancellor Merz
German Chancellor Friedrich Merz says the U.S. is being ‘humiliated’ by Iran’s leadership, questioning Washington’s exit strategy. CNBC’s Steve Sedgwick breaks down the German leader’s comments.
Novartis CEO warns reality of Trump’s drug pricing policy will set in over ‘the next 18 months’
Novartis’ CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a “very difficult situation.”
